LASIK Eye Surgery in India and UAE | Complete Patient Guide

• Age 18 years or older (ideally 21+), with a stable refraction for a minimum of 12 consecutive months (no prescription change greater than 0.50 D per year)

• Myopia up to −10.00 D (sphere), hyperopia up to +4.00 D, and astigmatism up to 6.00 D (higher ranges may be treatable with advanced platforms but require individual assessment)

• Adequate corneal thickness: minimum residual stromal bed of 250 µm post-ablation; total pre-operative pachymetry typically ≥480–500 µm for standard LASIK

• Normal corneal topography — no evidence of keratoconus, forme fruste keratoconus, or posterior corneal elevation on Scheimpflug tomography (Pentacam/Galilei)

• Pupil diameter assessment: photopic and scotopic pupil size measured; large scotopic pupils (>7 mm) may increase night-vision halo risk and may prompt selection of wavefront-guided or topography-guided profiles

• Adequate tear film and ocular surface: Schirmer test, TBUT (tear break-up time), and meibomian gland assessment performed; mild-to-moderate dry eye must be optimised pre-operatively

• Absence of active ocular disease: no keratitis, uveitis, glaucoma, significant cataract, or retinal pathology

• Systemic health: no uncontrolled autoimmune disease (e.g., lupus, rheumatoid arthritis), no keratoconus-associated connective tissue disorders, no immunosuppression that impairs corneal healing

• Not pregnant or breastfeeding (hormonal fluctuations alter refraction and healing)

Required Pre-Operative Diagnostics (conducted at GAF Healthcare partner centres):

• Scheimpflug corneal tomography (Pentacam HR or Galilei G4) — mandatory for keratoconus exclusion and pachymetry mapping

• Corneal wavefront aberrometry (iDesign, NIDEK OPD-Scan, or equivalent) for wavefront-guided ablation planning

• Specular microscopy (endothelial cell density and morphology)

• Optical biometry and axial length (IOLMaster 700 or equivalent)

• Full slit-lamp examination, dilated fundus evaluation, and applanation tonometry

• Tear film assessment: TBUT, Schirmer I test, MG (meibomian gland) evaluation, and if indicated, InflammaDry MMP-9 test

• Contact lenses must be removed prior to topography: soft lenses for a minimum of 3 days, rigid gas-permeable lenses for a minimum of 3 weeks

Contraindications:

• Keratoconus or ectatic corneal disease (any stage)

• Forme fruste keratoconus or suspicious topography patterns

• Corneal thickness insufficient to provide a safe residual stromal bed

• Severe dry eye syndrome unresponsive to medical optimisation

• Active herpetic keratitis or history of recurrent stromal herpetic disease

• Uncontrolled autoimmune or collagen vascular disease

• Severe amblyopia in either eye

• Pregnancy or lactation

• Unstable refraction

LASIK and its advanced variants exist on a spectrum of precision and invasiveness. Selecting the optimal platform requires integrating the patient's refractive profile, corneal anatomy, biomechanical risk score (Corvis Biomechanical Index, Belin/Ambrósio Enhanced Ectasia Display), lifestyle, and occupational demands.

1. Standard Wavefront-Optimised LASIK

Platform examples: Alcon WaveLight EX500 (500 Hz repetition rate, 1.4-second ablation per dioptre), SCHWIND AMARIS 1050RS. The femtosecond laser (e.g., IntraLase iFS, Ziemer LDV Z8, or ZEISS VisuMax 500) creates the corneal flap; the excimer laser ablates a pre-programmed aspherically optimised profile. This is the global standard of care for uncomplicated myopia and myopic astigmatism. Typical ablation zone: 6.5–6.75 mm optical zone with a 9.0 mm total ablation zone to minimise edge artefact.

2. Wavefront-Guided LASIK (Customised Ablation)

Platform examples: iDesign 2.0 (Johnson & Johnson Vision), NIDEK EC-5000. Wavefront aberrometry maps the eye's unique higher-order aberration (HOA) profile (Zernike polynomials, Strehl ratio) and customises the ablation to reduce pre-existing HOAs. Indicated for patients with significant pre-existing trefoil, coma, or spherical aberration, or those with high visual quality demands (aviators, surgeons, night drivers). Consistently superior contrast sensitivity and night-vision outcomes vs. wavefront-optimised in published randomised trials.

3. Topography-Guided LASIK (Contoura Vision)

Regulatory status: FDA-approved. Platform: WaveLight EX500 + TOPOLYZER VARIO topographer. Ablation is guided by 22,000 elevation data points from corneal topography, targeting micro-irregularities in the anterior corneal surface. FDA pivotal trial (PROWL-1 and PROWL-2) reported 65% of subjects achieving better-than-20/20 UCVA and superior subjective quality-of-vision scores. Particularly advantageous in patients with irregular astigmatism, prior orthokeratology, or mild anterior corneal irregularity.

4. SMILE (Small Incision Lenticule Extraction)

Platform: ZEISS VisuMax femtosecond laser (500 kHz or 1000 kHz). SMILE is a flapless, single-laser procedure in which the femtosecond laser creates a stromal lenticule of precise geometry within the intact cornea; the surgeon extracts the lenticule through a 2–4 mm incision using a dissector. No excimer laser is used. Advantages: preservation of corneal biomechanical integrity (Bowman's layer largely intact, fewer severed stromal lamellae), no flap-related complications, reduced post-operative dry eye severity vs. LASIK in prospective studies. Currently approved for myopia (up to −10.00 D) and myopic astigmatism (up to 5.00 D); hyperopic SMILE is under regulatory evaluation. Preferred for patients in contact-sport professions or with borderline dry eye.

5. PRK (Photorefractive Keratectomy) and Trans-PRK (Transepithelial PRK / LASEK)

No flap is created; the epithelium is removed (mechanically in PRK, by alcohol-assisted lifting in LASEK, or by direct excimer laser ablation in Trans-PRK / SCHWIND AMARIS no-touch). Excimer ablation is then performed directly on Bowman's layer. Recovery is slower (5–7 days of surface discomfort; functional vision in 5–10 days; stable refraction at 3 months) but the procedure eliminates all flap-related risks and preserves maximum stromal tissue. Indicated for thin corneas, flat corneas, patients with prior corneal surgery, or those at high risk of ocular trauma (military, contact sports). Mitomycin-C (0.02% for 12–20 seconds) is applied post-ablation for corrections >−4.00 D to mitigate subepithelial haze.

6. LASIK Enhancement (Re-Treatment)

If residual refraction persists at 3–6 months post-primary LASIK (documented stable refraction, adequate residual stromal bed ≥250 µm), the original flap can be lifted and additional ablation performed. Enhancement rates with modern platforms are below 3–5% for corrections within the intended treatment range.

Technology Differentiators at GAF Partner Centres:

• Eye-tracking systems: 7-dimensional (translational X/Y/Z + rotational cyclotorsion + pupil centration) active tracking at 1050 Hz (SCHWIND AMARIS) ensures ablation accuracy during involuntary microsaccades

• Iris recognition and cyclotorsion compensation: corrects for rotational head-tilt between supine ablation and upright topography capture — critical for astigmatic corrections

• Intraoperative pachymetry and OCT: real-time flap and stromal bed thickness confirmation

Phase 1 — Remote Pre-Consultation (Weeks 1–2 Before Travel) GAF Healthcare's clinical coordinators collect and transmit the patient's current spectacle/contact-lens prescription, previous ocular history, systemic medical history, and any available corneal topography to the partner surgeon. A video teleconsultation is scheduled for provisional candidacy assessment. The patient receives a preparation checklist: cease soft contact lens wear ≥3 days before arrival (rigid gas-permeable lenses ≥3 weeks); avoid eye makeup, perfume, and lotions on the day of surgery; arrange a companion for travel on the day of the procedure.

Phase 2 — Day of Arrival / Day −1 (Pre-Operative Workup) On the day of arrival or the morning before surgery, the patient undergoes a comprehensive pre-operative evaluation at the partner centre (typically 2–3 hours): slit-lamp examination, Scheimpflug tomography (Pentacam), aberrometry, specular microscopy, tear film assessment, applanation tonometry, and dilated fundus evaluation. The surgeon reviews all data, confirms the surgical plan (platform, ablation profile, optical zone, intended correction), and discusses risks, alternatives, and expected outcomes. Informed consent is obtained. Pre-operative topical antibiotic eye drops (e.g., moxifloxacin 0.5%) are commenced if the procedure is scheduled for the following day.

Phase 3 — Day of Surgery (Day 0) The patient arrives fasting of eye makeup; mild oral anxiolytic (e.g., diazepam 5 mg) may be offered if requested. Topical anaesthetic drops (proparacaine or oxybuprocaine) are instilled; no injection or general anaesthesia is required. The patient lies supine under the laser system. For LASIK: the femtosecond laser creates the corneal flap (15–30 seconds per eye under suction); the flap is lifted and the excimer laser delivers the ablation (20–60 seconds per eye depending on refractive target); the flap is repositioned and smoothed. For SMILE: a single femtosecond pass creates the lenticule and incision (25–30 seconds); the surgeon dissects and extracts the lenticule (~1–2 minutes). The bilateral procedure is completed in 15–20 minutes total. No sutures are placed. Post-operative drops are instilled (antibiotic + corticosteroid combination; lubricating drops). A clear protective shield is placed over each eye.

Phase 4 — Immediate Post-Operative Period (Hours 1–6, Day 0) The patient rests in the recovery area for 20–30 minutes. Mild lacrimation, photophobia, and a foreign-body sensation are expected for 2–6 hours and resolve spontaneously. Vision is typically functional (though hazy) within 2–4 hours for LASIK/SMILE. The patient is instructed not to rub eyes, to use prescribed drops, and to wear protective shields during sleep for the first week.

Phase 5 — Day 1 Post-Operative Review A mandatory slit-lamp examination at the partner centre confirms flap position (LASIK), epithelial integrity (SMILE/PRK), absence of interface debris or diffuse lamellar keratitis (DLK), and intraocular pressure. The majority of LASIK/SMILE patients achieve functional driving vision (≥6/12) by Day 1. Prescriptions confirmed: preservative-free lubricating drops (every 1–2 hours for the first month), topical fluoroquinolone antibiotic (4× daily for 1 week), topical corticosteroid (4× daily, tapered over 2–4 weeks). Strict protective sunglasses outdoors.

Phase 6 — Days 3–7: Fit-to-Fly Assessment If the Day 1 examination is clear, GAF Healthcare coordinates a fit-to-fly review. For LASIK and SMILE, most patients are cleared for short-haul flight (under 4 hours) from Day 3–5, provided there is no active DLK, significant epithelial defect, or intraocular pressure concern. Long-haul international flights (>6 hours) are recommended from Day 7–10. The cabin environment (low humidity, pressurisation) can exacerbate temporary dry eye; patients are advised to use preservative-free lubricating drops every 30–60 minutes during the flight and avoid reading screens throughout. For PRK patients, fit-to-fly is typically Day 7–10 after epithelial healing is confirmed and surface discomfort resolved.

Phase 7 — Medium-Term Recovery (Weeks 2–12) Vision stabilises progressively: approximately 80–90% of final outcome achieved by Day 7, 95% by 1 month, and 99% by 3 months. Patients are advised to avoid swimming pools and open water for 4 weeks, contact sports for 4 weeks (LASIK) or 1 week (SMILE), eye rubbing indefinitely (risk of flap displacement in LASIK, or ectasia trigger). Night-vision phenomena (halos, glare, starbursts) are common in the first 4–8 weeks and typically resolve as the cornea remodels; persistent symptoms beyond 3 months warrant topographic re-evaluation. Remote follow-up is facilitated by GAF Healthcare with the patient's local ophthalmologist.

Phase 8 — Final Review (Month 3–6) Refraction, UCVA, BCVA, corneal topography, and contrast sensitivity are assessed. If residual refractive error is clinically significant (>0.50 D) and the cornea supports it, enhancement is discussed. Keratometry and tomography stability confirms absence of post-LASIK ectasia (incidence <0.05% with modern screening protocols).